Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- EVT.F
- Price
- 5.83
- Stock movement up
- +- (%)
- Company name
- Evotec SE
- Exchange
- (F ,
- Currency
- EUR )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 1.04B
- Ent value
- 1.83B
- Price/Sales
- 1.33
- Price/Book
- 1.07
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -59.79%
- 3 year return
- -39.48%
- 5 year return
- -24.03%
- 10 year return
- 4.52%
Last updated: 2025-04-05
DIVIDENDS
EVT.F does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.33 |
| Price to Book | 1.07 |
| EV to Sales | 2.35 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 177.55M |
| EPS (TTM) | -0.97 |
| FCF per share (TTM) | -1.17 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 777.05M |
| Gross profit (TTM) | 106.45M |
| Operating income (TTM) | -98.72M |
| Net income (TTM) | -171.37M |
| EPS (TTM) | -0.97 |
| EPS (1y forward) | -0.20 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 13.70% |
| Operating margin (TTM) | -12.70% |
| Profit margin (TTM) | -22.05% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 231.30M |
| Net receivables | 97.74M |
| Total current assets | 698.10M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 1.99B |
| Accounts payable | 69.89M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 333.62M |
| Total liabilities | 1.02B |
| Shareholder's equity | 968.47M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -34.74M |
| Capital expenditures (TTM) | 173.20M |
| Free cash flow (TTM) | -207.94M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -17.69% |
| Return on Assets | -8.61% |
| Return on Invested Capital | -17.69% |
| Cash Return on Invested Capital | -21.47% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.72 |
| Daily high | 5.97 |
| Daily low | 5.72 |
| Daily Volume | 0K |
| All-time high | 185.50 |
| 1y analyst estimate | 11.04 |
| Beta | 0.98 |
| EPS (TTM) | -0.97 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 10 Jun 2025 |
Downside potential
Loading...
Downside potential data
| EVT.F | S&P500 | |
| Current price drop from All-time high | -96.85% | -12.44% |
| Highest price drop | -99.70% | -56.47% |
| Date of highest drop | 3 Mar 2009 | 9 Mar 2009 |
| Avg drop from high | -92.64% | -11.07% |
| Avg time to new high | 230 days | 12 days |
| Max time to new high | 6373 days | 1805 days |
COMPANY DETAILS
Marketcap
1.04B
Marketcap category
Small-cap
Description
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Employees
5007
Website
Investor relations
-
SEC filings
CEO
Country
Germany
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Evotec (NASDAQ:EVO) stands against other best German stocks...
April 2, 2025
Ongoing strategic partnership advances joint pipeline in neurodegeneration research Evotec receives a $20 million payment to further progress research HAMBURG, DE / ACCESS Newswire / March 4, 2025 / E...
March 4, 2025
Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025 Paul Hitchin appointed to succeed as Chief Financial Officer effective 1 March 2025 HAMBURG, GERMANY / ACCESS Newswire ...
February 26, 2025
Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m...
January 22, 2025
Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture earl...
December 11, 2024
Health care stocks were higher in Friday afternoon trading, with the NYSE Health Care Index and the
November 29, 2024
Halozyme withdraws its proposal to acquire Evotec for 11 euro per share in cash. The company maintains its 2024 revenue guidance. Shares up.
November 25, 2024
Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE (NASDAQ:EVO) for 11 euro ($11.44) per share in ...
November 22, 2024
Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480)(NASDAQ:EVO) Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 2...
November 22, 2024
Investing.com - Shares of Halozyme Therapeutics (NASDAQ:HALO) surged 12% at $51.2 before the opening bell on Friday after the company withdrew its €2 billion ($2.10 billion) proposal to acquire German...
November 22, 2024
Next page